Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE) (ADVANCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03873714|
Recruitment Status : Active, not recruiting
First Posted : March 13, 2019
Last Update Posted : August 31, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Intracranial Aneurysm||Device: Pipeline™ Vantage Embolization Device with Shield Technology™||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||140 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study of the Pipeline™ Vantage Embolization Device With Shield Technology™ for Endovascular Treatment of Wide-Necked Intracranial Aneurysms|
|Actual Study Start Date :||April 2, 2020|
|Estimated Primary Completion Date :||March 2024|
|Estimated Study Completion Date :||March 2026|
Experimental: Pipeline™ Vantage Embolization Device with Shield Technology™
Pipeline™ Vantage Embolization Device with Shield Technology™
Device: Pipeline™ Vantage Embolization Device with Shield Technology™
Pipeline™ Vantage Embolization Device with Shield Technology™
Other Name: Pipeline™ Vantage
- Safety: Incidence of major stroke or neurological death [ Time Frame: 1 year post-procedure ]Incidence of major stroke in the territory supplied by the treated artery or neurological death.
- Effectiveness: Incidence of complete aneurysm occlusion [ Time Frame: 1 year post-procedure ]Incidence of complete aneurysm occlusion (Raymond Roy Scale Class 1) without significant parent artery stenosis (≤ 50%) or retreatment of the target aneurysm
- Effectiveness: Incidence of successful device implantation [ Time Frame: Day 0 ]Incidence of successful device implantation at the target site
- Effectiveness: Incidence of complete aneurysm occlusion [ Time Frame: 1 and 3 years post-procedure ]Incidence of complete aneurysm occlusion (Raymond Roy Class 1)
- Effectiveness: Incidence of target aneurysm recurrence [ Time Frame: 1 and 3 years post-procedure ]Incidence of target aneurysm recurrence
- Safety: Incidence of major stroke [ Time Frame: 2 and 3 years post-procedure ]Incidence of major stroke in the territory supplied by the treated artery or neurological death
- Safety: Incidence of major stroke [ Time Frame: 30 days post-procedure ]Incidence of major stroke in the territory supplied by the treated artery or neurological death
- Safety: Incidence of delayed intraparenchymal hemorrhage [ Time Frame: >30 days post-procedure through 1 year post-procedure ]Incidence of delayed intraparenchymal hemorrhage
- Safety: Incidence of subjects with disabling strokes [ Time Frame: 1 year, 2 year, and 3 year post-procedure ]Incidence of subjects with disabling strokes that have a mRS decline to a score of 3 or more (mRS ≥ 3) due to a stroke-related cause assessed at a minimum of 90 days post-stroke event
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||22 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Inclusion Criteria (Imaging):
- Subject has a target intracranial aneurysm located in the internal carotid artery (up to the terminus).
- Subject has a target intracranial aneurysm with an aneurysm neck ≥4mm or a dome-to-neck ratio of < 2.
- Subject has a target intracranial aneurysm that has a parent vessel with diameter 1.5-5.0 mm distal/proximal to the target intracranial aneurysm.
Inclusion Criteria (Clinical):
- Subject (or subject's legally authorized representative) has provided written informed consent using the IRB and Medtronic approved Informed Consent Form and agrees to comply with protocol requirements. HIPAA/data protection authorization has been provided and signed by the subject (or subject's legally authorized representative).
- Age 22-80 years at the time of consent.
- Life expectancy ≥3 years
- Subject has a mRS ≤ 2 at baseline to be determined by a certified independent assessor at the site.
- Subject has already been selected for endovascular treatment of the target aneurysm.
- Subject's last recorded P2Y12 reaction units (PRU) value is between ≥60 and ≤200 prior to study procedure. For OUS sites, a Thromboelastogram (TEG) test may be carried out instead of the PRU test (depending on PRU test availability). In cases where TEG test is carried out, the subject should have a pre-procedure therapeutic ADP% between >30% to <90%.
- Subject has multiple increased risk factors for intracranial aneurysm rupture, including but not limited to, aneurysm morphology, smoking, hypertension, diabetes, age, prior and/or family history of rupture, and/or history of subarachnoid hemorrhage that may result in a benefit risk profile of endovascular treatment to outweigh the risks of intracranial aneurysm rupture during the subject's expected lifetime if left untreated.
Exclusion Criteria (Imaging):
- Subject has internal carotid artery bifurcation aneurysm.
- Aneurysms that arise from the Posterior Communicating Artery (PComm).
The internal carotid artery aneurysms of the C7 segment will be excluded under the following conditions:
- Observed fetal posterior communicating artery (PComm) of fetal origin (A PComm of fetal origin is defined as a small, hypoplastic, or absent P1 segment of the posterior cerebral artery (PCA) with the PComm artery supplying a majority of blood flow to the P2 and higher order segments of the PCA)
- PComm overlapping with the aneurysm neck
- PComm branch arising from the dome of the aneurysm
- Subject has aneurysm arising from internal carotid artery but is primarily fed by posterior circulation (i.e., retrograde flow from the basilar artery) as confirmed by DSA
Exclusion Criteria (Clinical):
- Subject requires treatment of another aneurysm (with another treatment modality) within the affected territory of the target aneurysm during the study period.
- Subject has received an intracranial implant (e.g. coils) in the area of the target intracranial aneurysm within the past 6 months prior to the study procedure.
- Subject has had a SAH and/or target aneurysm rupture in the past 30 days prior to the study procedure.
- Subject has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.
- Aneurysm vessel characteristics (e.g. parent vessel stenosis, irregular morphology) that would preclude the device from fully confirming to the parent vessel to reduce any risk of embolic complications, retreatment, or device movement.
- Subject has active vasospasm, malignant brain tumor or vascular malformation (e.g. arteriovascular malformation).
- History of major bleeding disorder (based on coagulation profile and platelet count) and/or subject presents with signs of active bleeding.
- Subject requires adjunctive device use (e.g. coils) during the index procedure.
- Subject has extradural target aneurysm <12mm which is not symptomatic or not exhibiting aneurysm growth (exception: unless it is a fusiform aneurysm <12 mm i.e., asymptomatic extradural fusiform aneurysms <12 mm can be included).
Any known contraindication to treatment with the Pipeline™ Vantage Embolization Device with Shield Technology™, or use of antiplatelet therapy including:
- Active bacterial infection
- Contraindication to DAPT agents
- Pre-existing stent is in place in the parent artery at the target intracranial aneurysm location
- Platelet count < 100 x 10^3 cells/mm^3 or known platelet dysfunction.
- The Investigator determines that the health of the subject or the validity of the study outcomes (e.g., high risk of neurologic events, conditions that may increase the chance of stroke) may be compromised by the subject's enrollment.
- Subject is pregnant or wishes to become pregnant during the first year of study participation.
- Subject is participating in another clinical trial at any time during the duration of the study that could confound the treatment or outcomes of this investigation.
- Subject with known allergy to platinum or cobalt chromium alloy (including the major elements platinum, cobalt, chromium, nickel or molybdenum).
- History of previous acute ischemic stroke
- Subject is unable to undergo DSA or CTA imaging at follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03873714
|United States, Florida|
|Baptist Medical Center Jacksonville|
|Jacksonville, Florida, United States, 32207|
|Jackson Memorial Hospital|
|Miami, Florida, United States, 33136|
|United States, New York|
|Stony Brook University Hospital|
|Stony Brook, New York, United States, 11794|
|Principal Investigator:||Pascal Jabbour, MD||Thomas Jefferson University|
|Principal Investigator:||Demetrius Lopes, MD||Advocate Health|
|Responsible Party:||Medtronic Neurovascular Clinical Affairs|
|Other Study ID Numbers:||
|First Posted:||March 13, 2019 Key Record Dates|
|Last Update Posted:||August 31, 2022|
|Last Verified:||August 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||No individual participant data will be available.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Device Product Not Approved or Cleared by U.S. FDA:||Yes|
Intracranial Arterial Diseases
Central Nervous System Diseases
Nervous System Diseases